Mario A. Salinas-Sanchez

Barcelona, CT 08035, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.

Journal: Blood advances

Published: December 04, 2025

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell Therapy.

Journal: Pharmaceutics

Published: October 27, 2025

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

Journal: Bone marrow transplantation

Published: August 11, 2025

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study.

Journal: Transplantation and cellular therapy

Published: August 07, 2025

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.

Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells.

Journal: HemaSphere

Published: February 05, 2024

Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.

Patients with aggressive B-cell lymphoma receiving CAR T-cell therapy have a low rate of severe infections despite lack of universal antibacterial and antifungal prophylaxis.

Journal: European journal of haematology

Published: January 08, 2024

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.

Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies.

Journal: Clinical kidney journal

Published: December 26, 2023

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 24, 2023

Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?

Journal: Blood advances

Published: October 20, 2023

Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.

Adenovirus-induced hemorrhagic cystitis after CD19-targeted chimeric antigen receptor T-cell therapy in a patient with large B-cell lymphoma.

Journal: Immunotherapy

Published: September 18, 2023

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.

PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.

Journal: EJHaem

Published: June 07, 2023

Showing 1-12 of 13

Last Updated: 09/26/2026